Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC by Jacqueline V. Aredo, MD, MS, Heather A. Wakelee, MD, Kavitha J. Ramchandran, MD, Joel W. Neal, MD, PhD, Maximilian Diehn, MD, PhD, Angela Bik-Yu Hui, PhD, Ameen Salahudeen, MD, PhD, Bernice Kwong, MD, Gerald J. Berry, MD, H. Henry Guo, MD, PhD, Kristen Cunanan, PhD, Shireen Vali, PhD, Danny Pancirer, BA, Vivian Tsang, MSN, Grace Hwang, MS, Monica Loza, BA, Brittany Johnson, BA, Isabelle Blanchard, BS, Sukhmani K. Padda, MD

Get full text

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy by Laura C Cappelli, Bernice Kwong, Jarushka Naidoo, Jonathan Leventhal, Mario E Lacouture, Meghan J Mooradian, Douglas B Johnson, Justine Cohen, Aparna Hegde, Steven T Chen, Riley Fadden, Leyre Zubiri, Shawn Kwatra, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Yevgeniy R Semenov, Nicole R LeBoeuf, Krista M Rubin, Anna K Dewan, Alina Markova, Allireza Alloo, Daniel Q Bach, Amina Bougrine, Leeann Burton, Mariana Castells, Lauren Guggina, Victor Huang, Benjamin Kaffenberger, Daniela Kroshinsky, Cecilia Larocca, Jon McDunn, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Maxwell Sauder, Sheila Shaigany, Afreen Shariff

Get full text